Biovie is trading 5.7% down at $1.32, alongside biotech weakness and a broader risk-off backdrop. - Elevated Treasury yields are weighing on risk appetite; available information supports sector pressure as context, not as an established cause of the decline. - Biovie’s investor-relations page lists its latest release as September 8. No new company-specific announcement explaining the decline was identified, and no specific intraday catalyst is established.